Merck said Jan. 28 that molnupiravir, the COVID-19 antiviral pill it developed with Ridgeback Therapeutics, showed “consistent antiviral activity” against the omicron variant.
Read the full post on Becker's Hospital Review - Healthcare News
Merck says its COVID-19 antiviral pill is effective against omicron
